CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+1.91%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$14.7B
AUM Growth
+$98M
(+0.67%)
Cap. Flow
+$48.4M
Cap. Flow
% of AUM
0.33%
Top 10 Holdings %
Top 10 Hldgs %
22.12%
Holding
956
New
63
Increased
332
Reduced
303
Closed
69
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$54.5M |
| 2 |
AstraZeneca
AZN
|
$46.3M |
| 3 |
Autodesk
ADSK
|
$40.5M |
| 4 |
Mercado Libre
MELI
|
$39.4M |
| 5 |
Amazon
AMZN
|
$31.1M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$92.5M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$85.8M |
| 3 |
Alibaba
BABA
|
$60.1M |
| 4 |
Merck
MRK
|
$49.2M |
| 5 |
MXIM
Maxim Integrated Products
MXIM
|
$48.5M |
Sector Composition
| 1 | Healthcare | 32.1% |
| 2 | Technology | 24.54% |
| 3 | Financials | 9.08% |
| 4 | Communication Services | 8.24% |
| 5 | Consumer Discretionary | 7.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
FIVE9
FIVN
$2.03B
| $13.7M | 0.09% |
+86,075
| New | +$13.7M |
|
227
Thomson Reuters
TRI
$80.6B
| $13.7M | 0.09% |
119,275
+47,745
| +67% | +$5.48M |
|
228
Intellia Therapeutics
NTLA
$1.25B
| $13.6M | 0.09% |
101,127
| – | – |
|
229
Revolution Medicines
RVMD
$7.28B
| $13.5M | 0.09% |
489,382
+95,312
| +24% | +$2.62M |
|
230
Union Pacific
UNP
$132B
| $13.2M | 0.09% |
64,402
-4,328
| -6% | -$884K |
|
231
Edwards Lifesciences
EW
$47.5B
| $13M | 0.09% |
114,949
+2,071
| +2% | +$234K |
|
232
Louisiana-Pacific
LPX
$6.74B
| $12.9M | 0.09% |
210,842
+82,094
| +64% | +$5.04M |
|
233
MacroGenics
MGNX
$123M
| $12.7M | 0.09% |
608,523
| – | – |
|
234
Ecolab
ECL
$78B
| $12.7M | 0.09% |
60,961
-5,548
| -8% | -$1.16M |
|
235
American Express
AXP
$230B
| $12.6M | 0.09% |
75,238
+22,509
| +43% | +$3.77M |
|
236
NeoGenomics
NEO
$1.04B
| $12.5M | 0.09% |
260,120
+72,788
| +39% | +$3.51M |
|
237
Sportsman's Warehouse
SPWH
$115M
| $12.5M | 0.08% |
709,064
| – | – |
|
238
AT&T
T
$212B
| $12.4M | 0.08% |
609,163
-31,617
| -5% | -$645K |
|
|
CVA
239
DELISTED
Covanta Holding Corporation
CVA
| $12.4M | 0.08% |
+615,930
| New | +$12.4M |
|
240
Arrowhead Research
ARWR
$3.87B
| $12.3M | 0.08% |
196,408
| – | – |
|
241
Masco
MAS
$15.5B
| $12.2M | 0.08% |
220,195
-68,659
| -24% | -$3.81M |
|
242
BioAtla
BCAB
$29.3M
| $11.9M | 0.08% |
404,636
+275,038
| +212% | +$8.1M |
|
|
NGM
243
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $11.9M | 0.08% |
564,059
| – | – |
|
244
Avantor
AVTR
$8.99B
| $11.8M | 0.08% |
288,432
-64,230
| -18% | -$2.63M |
|
245
TG Therapeutics
TGTX
$5.06B
| $11.8M | 0.08% |
353,983
| – | – |
|
|
UMPQ
246
DELISTED
Umpqua Holdings Corp
UMPQ
| $11.8M | 0.08% |
581,439
+194,023
| +50% | +$3.93M |
|
247
Zebra Technologies
ZBRA
$15.8B
| $11.6M | 0.08% |
22,528
+9,475
| +73% | +$4.88M |
|
|
CHNG
248
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $11.6M | 0.08% |
553,958
| – | – |
|
|
KDNY
249
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.5M | 0.08% |
902,537
+27,413
| +3% | +$350K |
|
250
Pacira BioSciences
PCRX
$1.2B
| $11.5M | 0.08% |
+204,960
| New | +$11.5M |
|